UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
32.65
+2.86 (9.60%)
Nov 19, 2026, 1:36 PM EST - Market open
UroGen Pharma Stock Forecast
Stock Price Forecast
According to 7 analysts polled by S&P Global, UroGen Pharma stock has a consensus rating of "Strong Buy" and an average price target of $60.71. The average 1-year stock price forecast is 85.94% higher than the current stock price, while the lowest is $54 (+65.39%) and the highest is $75 (+129.71%).
Price Target: $60.71 (+85.94%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for UroGen Pharma stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '26 | Jul '26 | Aug '26 | Sep '26 | Oct '26 | Nov '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 6 | 6 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 8 | 8 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $58 | Buy | Maintains | $58 | +77.64% | Nov 5, 2026 |
| Ladenburg Thalmann & Co. | Ladenburg Thalmann & Co. | Buy Maintains $65 → $62 | Buy | Maintains | $65 → $62 | +89.89% | Nov 5, 2026 |
| Oppenheimer | Oppenheimer | Buy Reiterates $60 | Buy | Reiterates | $60 | +83.77% | Nov 5, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $58 → $56 | Buy | Maintains | $58 → $56 | +71.52% | Nov 5, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $75 | Buy | Reiterates | $75 | +129.71% | Nov 3, 2026 |
Financial Forecast
Revenue This Year
319.58M
from 109.79M
Increased by 191.08%
Revenue Next Year
534.79M
from 319.58M
Increased by 67.34%
EPS This Year
-0.30
from -3.19
EPS Next Year
2.56
from -0.30
EPS and Forward PE are based on non-GAAP adjusted numbers.